Uterine Fibroid Treatment Device Market Size 2024-2028

The uterine fibroid treatment device market size is estimated to increase by USD 3.03 billion at a CAGR of 9.45% between 2023 and 2028. Market growth will be bolstered by several key factors, including increasing healthcare expenditure, a rising prevalence of uterine fibroids, and enhanced awareness regarding treatment options for this condition. As healthcare spending continues to rise worldwide, there is a corresponding increase in investment and demand for effective treatment solutions, such as laparoscopic devices, particularly for common issues like uterine fibroids. The growing incidence of uterine fibroids among women further influences market dynamics, highlighting the need for innovative therapies to address these healthcare challenges. Simultaneously, increased awareness among both patients and healthcare providers about available treatment options promotes early diagnosis and intervention, thereby improving patient outcomes and driving market growth. Modern OB/GYN practices are progressively adopting these devices to deliver effective treatment options that enhance patient recovery, including the use of uterine manipulators, which reflect advancements in medical technology tailored to meet the specific needs of uterine fibroid patients worldwide.

What will be the Size of the Uterine Fibroid Treatment Device Market During the Forecast Period?

To learn more about the market forecast report, Request Free Sample

Uterine Fibroid Treatment Device Market Segmentation

The uterine fibroid treatment device market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Therapeutic Area Outlook
  • Invasive treatment
  • Minimally invasive treatment
  • Non-invasive treatment

• Technology Outlook
  • Surgical techniques
  • Laparoscopic techniques
  • Ablation techniques
  • Embolization techniques

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • South America
    • Chile
    • Argentina
    • Brazil
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

The invasive treatment segment is expected to see substantial growth during the forecast period. This segment encompasses surgical methods that involve invasive procedures to remove or destroy fibroids. Currently, it commands a considerable share of the market, as many women continue to choose surgical options as the standard approach for treating fibroids. Examples of invasive treatments for fibroids include hysterectomy, myomectomy, and other surgical procedures.

Get a glance at the market contribution of various segments. View the PDF Sample

The invasive treatment segment was valued at USD 1.74 billion in 2018. The demand for these treatments is rising for several reasons, including the increasing incidence of uterine fibroids among women. Traditional surgical procedures allow physicians to accurately remove fibroids with lower risks compared to alternative treatments. Invasive methods, such as laparoscopic ablation, also provide a permanent solution to fibroids, alleviating debilitating symptoms.

However, the choice of invasive treatment methods is influenced by factors such as the size, number, and location of the fibroids, as well as the patient's age and reproductive status. Despite the benefits of invasive treatments, minimally invasive and noninvasive options, such as MRgFUS, are becoming more popular due to their shorter recovery times, reduced risk of complications, and minimal scarring. Consequently, the growing preference for these alternatives is expected to hinder the growth of the invasive treatment segment during the forecast period.

Key Region

For more insights on the market share of various regions, Download PDF Sample now!

North America is projected to account for 33% of the growth in the global market during the forecast period. Analysts from Technavio have provided a detailed analysis of the regional trends and drivers influencing market dynamics. In this region, the US and Canada are the primary contributors to market growth. The North American market has experienced steady growth in recent years, driven by several factors. A significant driver is the high prevalence of uterine fibroids among women in the region. According to the National Institutes of Health, approximately 80% of women in the US will develop fibroids at some point in their lives. Additionally, the rising adoption of minimally invasive techniques and noninvasive treatments is further propelling the growth of the uterine fibroid (UF) treatment device market in the region. Furthermore, government initiatives aimed at supporting women's health, including research funding and healthcare programs, are also contributing to the expansion of the uterine fibroid treatment device market in North America.

Uterine Fibroid Treatment Device Market Dynamics

The market is responding to the rising demand for minimally invasive procedures to manage conditions such as benign tumors that affect smooth muscle cells in the uterus. These tumors often lead to symptoms like excessive menstrual bleeding, pelvic pain, and infertility, primarily impacting middle-aged women. Key risk factors include hypertension, obesity, and dietary influences, which contribute to varying prevalence rates among different racial groups and those with a family history of the condition, particularly in premenopausal women. Traditional methods, such as surgical removal of the uterus, are increasingly being replaced by less invasive techniques and advanced technologies, including morcellators and collagen-degrading enzymes, which provide non-surgical alternatives with lower risks of severe complications. Modern OB/GYN practices are adopting these medical devices to offer effective treatment options that improve patient outcomes and recovery, such as the use of uterine manipulators.

Key Market Driver

An increase in healthcare expenditure is a primary driver of market growth. According to the National Health Institute (NIH), global healthcare spending was estimated to have risen by 5.8% in 2021, reaching USD 8.8 trillion. Countries like India and China are expected to see continued growth in healthcare spending, aligning with their economic development. As a result, these developing economies are becoming significant markets for healthcare companies. Meeting the needs of these nations will necessitate technological advancements and innovations in delivery and business models from healthcare providers.

Furthermore, the rise in healthcare expenditure is anticipated to boost the demand for medical technologies, subsequently increasing the need for uterine fibroid (UF) treatment devices. Therefore, the growing public and private healthcare investments in both developed and developing countries are projected to support the expansion of the uterine fibroid treatment device market during the forecast period.

Primary Market Trends

Improving healthcare systems in emerging economies is a key trend shaping the global uterine fibroid (UF) treatment device market. Countries such as Brazil, Russia, India, China, Saudi Arabia, and Mexico represent significantly underserved markets for healthcare products and services, including medical devices. These nations collectively account for more than 50% of the global GDP. The BRICS nations, Brazil, Russia, India, China, and South Africa, are among the fastest-growing economies globally, with population growth in these regions expected to drive increased demand for medical devices during the forecast period.

While emerging local companies in developing nations are striving to create innovative products using local materials at affordable prices, there remains substantial potential for established global companies in these markets. The healthcare infrastructure in these regions has attracted the interest of global institutional investors. Consequently, as healthcare infrastructure improves, emerging economies are poised for significant growth opportunities for medical devices, including tumor ablation technologies. Tumor ablation, which involves the destruction of tumors using techniques such as radiofrequency or microwave ablation, is vital in cancer treatment and is anticipated to see increased adoption in developing regions. This advancement in medical technology is expected to positively influence the growth of the uterine fibroid treatment device market during the forecast period, addressing essential healthcare needs in these expanding markets.

Major Market Challenge

The high cost of fibroid treatment presents a significant challenge to the growth of the global uterine fibroid (UF) treatment device market. The expense associated with these devices and procedures can be considerable, creating a financial barrier that hinders market expansion. Many patients, particularly those without insurance coverage, may find the costs prohibitive, leading to reduced demand for these treatment options. This financial burden can limit the availability and adoption of these devices, impacting healthcare providers' and hospitals' ability to invest in advanced technologies.

Additionally, the expenses related to purchasing, maintaining, and upgrading these devices may deter some healthcare providers from adopting new and innovative solutions, resulting in delays in bringing these technologies to market. The lack of insurance coverage for fibroid treatment procedures, especially in developing economies such as India, poses another significant challenge, as many patients may struggle to afford these treatments. This situation can lead to non-adherence to prescribed therapies, further obstructing growth in the UF treatment device market. Therefore, the high costs associated with fibroid treatment are expected to impede market growth during the forecast period.

Customer Landscape

The uterine fibroid treatment device market report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the UF treatment device market forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Uterine Fibroid Treatment Device Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Boston Scientific Corp.: The company offers uterine fibroid treatment device such as Bead Block device.

The uterine fibroid treatment device market research and growth report also includes detailed analyses of the competitive landscape of the market and information about 15 market players, including:

• Conmed Corp.
• Gynesonics Inc.
• Hologic Inc.
• INSIGHTEC Ltd.
• KARL STORZ SE and Co. KG
• Lumenis Be Ltd
• Medtronic Plc
• Merit Medical Systems Inc.
• Minerva Surgical Inc.
• Olympus Corp.
• The Cooper Companies Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Market Analyst Overview

The market addresses the diverse needs of patients suffering from benign tumors in the muscular wall of the uterus, commonly referred to as uterine myomas or leiomyomas. Symptoms such as heavy menstrual bleeding (HMB), abdominal pressure, pain, and increased urinary frequency significantly affect reproductive health and overall quality of life. Traditionally, these conditions have been treated through surgical removal of the uterus or other open surgeries. However, the market is increasingly focusing on minimally invasive fibroid surgeries, including radiofrequency ablation (RFA) with RF ablation devices and MRI-guided focused ultrasound. These modern techniques offer benefits such as smaller incisions, reduced post-operative pain, and quicker recovery times.

Non-invasive treatments, including collagen-degrading enzymes, gonadotropin-releasing hormone agonists (e.g., leuprolide, goserelin, triptorelin), and uterine artery embolization (UAE), are gaining traction due to their effectiveness and minimal side effects. Initiatives like Fibroids Awareness Month, along with advocacy organizations such as the White Dress Project and Healthy Women, enhance awareness and support for UF patients through education and access to innovative treatments via outpatient centers, home healthcare services, and telemedicine platforms. Additionally, non-surgical alternatives utilizing collagen-degrading enzymes are being investigated as viable substitutes for traditional surgical removal. Ablation, which involves the removal or destruction of tissue, is a key focus area, with laparoscopic ablation employing a laparoscope to target abnormal tissue. Laparoscopic devices facilitate these minimally invasive procedures through small incisions, leading to faster recovery and reduced scarring.

The uterine fibroid treatment device market is expanding rapidly, driven by increasing demand for non-invasive treatment options like MRI-guided focused ultrasound and other non-surgical alternatives. Women experiencing symptoms such as frequent urination, abdominal pressure and pain, bloating, anemia, and reproductive dysfunction from non-cancerous tumors are actively seeking effective solutions. While surgical removal of the uterus remains an option for some, the popularity of minimally invasive fibroid surgeries is on the rise. Gonadotropin-releasing hormone agonists, progesterone, and mefenamic acid are commonly used to manage symptoms. These contemporary approaches significantly reduce post-operative pain, offering promising alternatives to traditional surgical methods. The non-invasive treatment segment is a key driver of market growth, effectively addressing patient needs for safer and less invasive interventions

.

View PDF Sample

What are the Key Data Covered in this Uterine Fibroid Treatment Device Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market vendors

We can help! Our analysts can customize this uterine fibroid treatment device market research report to meet your requirements.

Get in touch